INTERNATIONAL JOURNAL OF CANCER-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=)]

2022-08-23 ms2000002114558983

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤;微生物
经验分享：3.24咨询是否接收散稿；
3.28回复感兴趣，欢迎投稿；
3.31投稿；
4.4under review;
4.27major revisions；
6.20修回；
6.21外审；
7.13major revisions；
8.11修回后决定；
8.15接收。
过程很艰辛，审稿人很专业，要求比较高。

74 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=)]

2022-11-12 capoex

投稿命中率:25.0
偏重的研究方向：实体肿瘤
经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中

67 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=)]

2019-12-14 0722

那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？

120 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=)]

2022-02-13 ZZLLZZ

偏重的研究方向：肿瘤;Environmental Research
经验分享：最近审的特别慢，一审拒稿特别慢，吐了

53 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=)]

2020-05-18 1486c94em67暂无昵称

审稿速度:2.0 | 投稿命中率:50.0
经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验

156 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=)]

2023-12-29 ms3000001161396804 来自黑龙江省

偏重的研究方向：DNA损伤修复
经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢

45 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=)]

2024-04-27 146449eem63暂无昵称来自上海

投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审

11 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=)]

2022-08-27 ms5000001852951271

偏重的研究方向：肿瘤;biomarker
经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？

0 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=)]

2022-07-04 ay

6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de

63 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;微生物 经验分享：3.24咨询是否接收散稿； 3.28回复感兴趣，欢迎投稿； 3.31投稿； 4.4under review; 4.27major revisions； 6.20修回； 6.21外审； 7.13major revisions； 8.11修回后决定； 8.15接收。 过程很艰辛，审稿人很专业，要求比较高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0 偏重的研究方向：实体肿瘤 经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581478, encodeId=d69d5814e870, content=那这个杂志到底需要不需要提供原始数据和细胞鉴定证明呢？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/32cffa614258a6e7082d8f21e9d7b0b4.jpg, createdBy=01175246527, createdName=0722, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193026, encodeId=65ae119302640, content=偏重的研究方向：肿瘤;Environmental Research 经验分享：最近审的特别慢，一审拒稿特别慢，吐了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=62785559987, createdName=ZZLLZZ, createdTime=Sun Feb 13 18:13:59 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591190, encodeId=aacc591190fc, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：评审了一个半月被拒。结肠癌化疗药物相关实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Mon May 18 00:00:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床 经验分享：2021年12月13日提交； 2022年2月11日大修； 3月14日修回； 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=)]

2022-04-05 llmmzz0000

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;临床
经验分享：2021年12月13日提交；
2022年2月11日大修；
3月14日修回；
3月29日接收。

46 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务